According to Xuantai Pharmaceutical's announcement, the company received a notice from the National Drug Administration of Malaysia that the generic application for sevilam carbonate tablets has been officially approved, and the marketing license number is MAL26076040ACZ. This drug is suitable for controlling hyperphosphatemia in adult patients with chronic kidney disease receiving dialysis treatment. This approval indicates that the company is qualified to sell in the Malaysian market, which is conducive to expanding the size of the Southeast Asian market and enriching the product lineup. However, product sales are affected by multiple factors, and there is uncertainty about the impact on performance in the short term.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.